The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2024 | Activating the immune system with CELMoDs to treat multiple myeloma
Charlotte Pawlyn, BA, MBBChir, MRCP, PhD, FRCPath, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK, discusses novel immune-activating agents for treating myeloma. Cereblon E3 ligase modulators (CELMoDs) enhance T-cell activity, even in cells that have been exhausted from previous T-cell engager therapies, and boost NK-cell efficacy against myeloma cells. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
